Table 1—

Pharmacokinetic parameters after NN2211 administration to healthy male subjects

Dose (μg/kg)AUC (n · nmol−1 · l−1)Absolute bioavailability (%)Cmax (nmol/l)tmax (h)Clearance (ml · min−1 · kg−1)Volume of distribution (l/kg)t1/2* (h)
1.25 s.c.15 ± 60.49 ± 0.199.6 ± 1.914
2.5 s.c.60 ± 292.3 ± 0.7010 ± 3.411
5.0 i.v.216 ± 430.10 ± 0.020.07 ± 0.018.1
5.0 s.c.134 ± 10855 ± 374.5 ± 3.49.3 ± 3.215
10.0 s.c.235 ± 337.9 ± 2.712 ± 6.014
12.5 s.c.283 ± 3110 ± 2.711 ± 2.412
15.0 s.c.384 ± 5713 ± 2.011 ± 1.113
17.5 s.c.451 ± 6517 ± 3.011 ± 1.011
20.0 s.c.523 ± 10520 ± 3.010 ± 1.311
  • Data are mean pharmacokinetic parameters ± SD after intravenous and subcutaneous administration of NN2211 to healthy male subjects (n = 6 unless otherwise indicated). tmax, time to maximal plasma concentration; t1/2, half-life.

  • *

    * Harmonic mean;

  • n = 9;

  • n = 4.